We are live on ! Find out more
BCM

BIOS Capital Management Portfolio holdings

AUM $41.7M
1-Year Est. Return 34.92%
This Fund
S&P 500
This Quarter Est. Return
-10.71%
1 Year Est. Return
+34.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$72.6M
AUM Growth
-$6.6M
Cap. Flow
+$2.67M
Cap. Flow %
3.68%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
2
Reduced
2
Closed
–
Avg Time Held
2 quarters
Top 10 Avg Time Held
2 quarters
Top 20 Avg Time Held
2 quarters

Top Buys

Rank Stock Value
1
IRD icon
Opus Genetics
IRD
+$2.49M
2
ACTU icon
Actuate Therapeutics
ACTU
+$624K

Top Sells

Rank Stock Value
1
LTRN icon
Lantern Pharma
LTRN
+$445K
2
INAB icon
IN8bio
INAB
+$12

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ACTU icon
1
Actuate Therapeutics
ACTU
$14.7M
$60.9M 83.89%
9,965,079
+71,428
+0.7% +$624K
2024 Q4
2 quarters
IRD icon
2
Opus Genetics
IRD
$387M
$3.46M 4.77%
3,683,429
+2,688,180
+270% +$2.49M
2024 Q4
2 quarters
LTRN icon
3
Lantern Pharma
LTRN
$12.1M
$3.4M 4.68%
1,075,952
-131,757
-11% -$445K
2024 Q4
2 quarters
RNTX icon
4
Rein Therapeutics
RNTX
$68.5M
$2.37M 3.26%
1,690,751
– –
2024 Q4
2 quarters
CGTX icon
5
Cognition Therapeutics
CGTX
$83.4M
$1.86M 2.56%
6,000,000
– –
2024 Q4
2 quarters
INAB icon
6
IN8bio
INAB
$13.2M
$599K 0.83%
286,664
-3
-0% -$12
2024 Q4
2 quarters

Similar funds

BP
Baypointe Partners Stamford, Connecticut $41.7M AUM 18.93% 1-Year Est. Return
MAMNY
Marathon Asset Management (New York) New York $41.5M AUM 245.82% 1-Year Est. Return
AP
Atairos Partners Bryn Mawr, Pennsylvania $41.1M AUM 4.36% 1-Year Est. Return
CIC
Cincinnati Indemnity Company Fairfield, Ohio $41.1M AUM 6.63% 1-Year Est. Return
GCM
GuideStone Capital Management Dallas, Texas $42.5M AUM 41.03% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.8M AUM 25.68% 1-Year Est. Return
GC
Gruss & Co West Palm Beach, Florida $40.8M AUM 44% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $40.6M AUM 156.55% 1-Year Est. Return

BIOS Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, BIOS Capital Management held 6 positions worth $72.6M, down 8.3% from $79.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

BIOS Capital Management deployed $2.67M of net new capital in Q2 2025, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Lantern Pharma, an estimated $445K trimmed.

  • BIOS Capital Management added most to Opus Genetics in Q2 2025, an estimated $2.49M increase.
  • BIOS Capital Management's biggest Q2 2025 reduction was Lantern Pharma, cutting an estimated $445K.
  • BIOS Capital Management's ten largest holdings make up 100% of its $72.6M portfolio in Q2 2025.
  • BIOS Capital Management opened 0 new positions and closed 0 in Q2 2025.
  • BIOS Capital Management's portfolio value fell 8.3% quarter-over-quarter to $72.6M.

Based on BIOS Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.